Mesenchymoangioblast-derived mesenchymal stromal cells inhibit cell damage, tissue damage and improve peripheral blood flow following hindlimb ischemic injury in mice

Published:December 28, 2015DOI:


      Background aims

      Existing treatments have limited success in modifying the course of peripheral artery disease, which may eventually lead to limb-threatening ulcers and amputation. Cellular therapies have the potential to provide a new treatment option for this condition, but isolation of cells by conventional means has limitations with respect to reproducibility and scalability.


      Induced pluripotent stem cells (iPSCs) were differentiated into precursor cells known as mesenchymoangioblasts (MCAs) and subsequently into mesenchymal stromal cells (MSCs). Hindlimb ischemia in mice was created by ligating both the iliac and femoral arteries of one hindlimb. Immediately after surgery, each animal received intramuscular injections of 5 × 106 cells or media in the ischemic limb. Toe necrosis was assessed visually, and hindlimb blood flow was measured by laser Doppler using a set region of interest (ROI) and by tracing the entire foot. Myofiber heterogeneity, nuclear centralization, fatty degeneration, fibrosis and capillary angiogenesis in the gastrocnemius muscle were assessed histologically.


      Blood flow in the MCA-derived MSC-treated animals was higher at each day (P <0.006), and these mice recovered faster than control animals (3.6 vs. 2.5 for set ROI; 7.5 vs. 4.1 foot tracing; slope; P <0.001). There was significantly less myofiber heterogeneity, nuclear centralization, fatty degeneration and fibrosis in MCA-derived MSC-treated animals, indicating less tissue damage.


      MCA-derived MSCs improved limb blood flow, reduced necrosis and maintained muscle mass and gross muscle appearance. We conclude that MCA-derived MSCs have a significant and protective effect against ischemic insults.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Abdulhannan P.
        • Russell D.A.
        • Homer-Vanniasinkam S.
        Peripheral arterial disease: a literature review.
        Br Med Bull. 2012; 104: 21-39
        • Selvin E.
        • Erlinger T.P.
        Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999–2000.
        Circulation. 2004; 110: 738-743
        • Raval Z.
        • Losordo D.W.
        Cell therapy of peripheral arterial disease: from experimental findings to clinical trials.
        Circ Res. 2013; 112: 1288-1302
        • Golomb B.A.
        • Dang T.T.
        • Criqui M.H.
        Peripheral arterial disease: morbidity and mortality implications.
        Circulation. 2006; 114: 688-699
        • Liew A.
        • O'Brien T.
        Therapeutic potential for mesenchymal stem cell transplantation in critical limb ischemia.
        Stem Cell Res Ther. 2012; 3: 28
        • Lawall H.
        • Bramlage P.
        • Amann B.
        Stem cell and progenitor cell therapy in peripheral artery disease.
        Thromb Haemost. 2010; 103: 696-709
        • Le Blanc K.
        • Tammik C.
        • Rosendahl K.
        • Zetterberg E.
        • Ringdén O.
        HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells.
        Exp Hematol. 2003; 31: 890-896
        • Karantalis V.
        • Hare J.M.
        Use of mesenchymal stem cells for therapy of cardiac disease.
        Circ Res. 2015; 116: 1413-1430
        • Wagner W.
        • Horn P.
        • Castoldi M.
        • Diehlmann A.
        • Bork S.
        • Saffrich R.
        • et al.
        Replicative senescence of mesenchymal stem cells: a continuous and organized process.
        PLoS ONE. 2008; 3: e2213
        • Phinney D.D.
        Functional heterogeneity of mesenchymal stem cells: implications for cell therapy.
        J Cell Biochem. 2012; 113: 2806-2812
        • Lei Y.
        • Schaffer D.V.
        A fully defined and scalable 3D culture system for human pluripotent stem cell expansion and differentiation.
        Proc Natl Acad Sci USA. 2013; 110: E5039-48
        • Rufaihah A.J.
        • Huang N.F.
        • Jamé S.
        • Lee J.C.
        • Nguyen H.N.
        • Byers B.
        • et al.
        Endothelial cells derived from human iPSCS increase capillary density and improve perfusion in a mouse model of peripheral arterial disease.
        Arterioscler Thromb Vasc Biol. 2011; 31: e72-9
        • Lai W.H.
        • Ho J.C.
        • Chan Y.C.
        • Ng J.H.
        • Au K.W.
        • Wong L.Y.
        • et al.
        Attenuation of hind-limb ischemia in mice with endothelial-like cells derived from different sources of human stem cells.
        PLoS ONE. 2013; 8: e57876
        • Dar A.
        • Domev H.
        • Ben-Yosef O.
        • Tzukerman M.
        • Zeevi-Levin N.
        • Novak A.
        • et al.
        Multipotent vasculogenic pericytes from human pluripotent stem cells promote recovery of murine ischemic limb.
        Circulation. 2012; 125: 87-99
        • Lian Q.
        • Zhang Y.
        • Zhang J.
        • Zhang H.K.
        • Wu X.
        • Zhang Y.
        • et al.
        Functional mesenchymal stem cells derived from human induced pluripotent stem cells attenuate limb ischemia in mice.
        Circulation. 2010; 121: 1113-1123
        • Dominici M.
        • Le Blanc K.
        • Mueller I.
        • Slaper-Cortenbach I.
        • Marini F.C.
        • Krause D.S.
        • et al.
        Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.
        Cytotherapy. 2006; 8: 315-317
        • Lian Q.
        • Lye E.
        • Suan Yeo K.
        • Khia Way Tan E.
        • Salto-Tellez M.
        • Liu T.M.
        • et al.
        Derivation of clinically compliant MSCs from CD105+, CD24- differentiated human ESCs.
        Stem Cells. 2007; 25: 425-436
        • Takashima Y.
        • Era T.
        • Nakao K.
        • Kondo S.
        • Kasuga M.
        • Smith A.G.
        • et al.
        Neuroepithelial cells supply an initial transient wave of MSC differentiation.
        Cell. 2007; 129: 1377-1388
        • Dennis J.E.
        • Charbord P.
        Origin and differentiation of human and murine stroma.
        Stem Cells. 2002; 20: 205-214
        • Isern J.
        • García-García A.
        • Martín A.M.
        • Arranz L.
        • Martín-Pérez D.
        • Torroja C.
        • et al.
        The neural crest is a source of mesenchymal stem cells with specialized hematopoietic stem cell niche function.
        eLife. 2014; 3: e03696
        • Vodyanik M.A.
        • Yu J.
        • Zhang X.
        • Tian S.
        • Stewart R.
        • Thomson J.
        • et al.
        A mesoderm-derived precursor for mesenchymal stem and endothelial cells.
        Cell Stem Cell. 2010; 7: 718-729
        • Yu J.
        • Vodyanik M.A.
        • Smuga-Otto K.
        • Antosiewicz-Bourget J.
        • Frane J.L.
        • Tian S.
        • et al.
        Induced pluripotent stem cell lines derived from human somatic cells.
        Science. 2007; 318: 1917-1920
        • Mendicino M.
        • Bailey A.M.
        • Wonnacott K.
        • Puri R.K.
        • Bauer S.R.
        MSC-based product characterization for clinical trials: an FDA perspective.
        Cell Stem Cell. 2014; 14: 141-145
        • Sharma R.R.
        • Pollock K.
        • Hubel A.
        • McKenna D.
        Mesenchymal stem or stromal cells: a review of clinical applications and manufacturing practices.
        Transfusion. 2014; : 1418-1437
        • Simons M.
        Angiogenesis: where do we stand now?.
        Circulation. 2005; 11: 1556-1566
        • Shireman P.K.
        The chemokine system in arteriogenesis and hind limb ischemia.
        J Vasc Surg. 2007; 45: A48-56
        • Korthuis R.J.
        Skeletal muscle circulation.
        Morgan & Claypool Life Sciences, San Rafael (CA)2011
        • Limbourg A.
        • Korff T.
        • Napp L.C.
        • Schaper W.
        • Drexler H.
        • Limbourg F.P.
        Evaluation of postnatal arteriogenesis and angiogenesis in a mouse model of hind-limb ischemia.
        Nat Protoc. 2009; 4: 1737-1746